↓ Skip to main content

Dove Medical Press

Article Metrics

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, June 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
14 Mendeley
Title
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
Published in
International Journal of Chronic Obstructive Pulmonary Disease, June 2015
DOI 10.2147/copd.s83205
Pubmed ID
Authors

Paul Zarogoulidis, Kelly Domvri, Konstantinos Porpodis, Konstantinos Zarogoulidis, Alexandra Liaka, Violeta Kikidaki, John Organtzis, Sofia Lampaki, Dimitris Petridis, Olga Hatzizisi, Katerina Tsirgogianni, Ioannis Kioumis, Antonis Papaiwannou

Abstract

A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory cells involved in triggering exacerbations of COPD. The objective of the current study was to evaluate roflumilast for its contribution to phagocytic activity in COPD patients. Twenty-one patients diagnosed with COPD received roflumilast once daily for 6 months in combination with fluticasone (an inhaled corticosteroid), salmeterol (a long-acting β2-agonist), and tiotropium (a long-acting muscarinic antagonist) or combinations of these agents. The main inclusion criterion was stable disease for at least the previous 30 days. Neutrophils and spirometric changes, ie, forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), were measured in the COPD patients at indicated time points. The first sample was taken before receiving roflumilast, the second 3 months later, and the third after 6 months. Examination of defective phagocytosis was done by flow cytometry using a FagoFlowEx(®) kit. The statistical analysis was performed using Statistica software. Our results indicate that phagocytic activity was increased after 3 and 6 months of treatment when compared with baseline (P<0.001). Similarly, FVC and FEV1 were also increased during the 6-month period, but only FVC differed significantly from baseline (P<0.001). Although the number of patients in this study was limited, our results indicate that roflumilast induces phagocytic activity, which improves lung function.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 14%
Student > Bachelor 1 7%
Student > Doctoral Student 1 7%
Librarian 1 7%
Student > Ph. D. Student 1 7%
Other 3 21%
Unknown 5 36%
Readers by discipline Count As %
Medicine and Dentistry 4 29%
Computer Science 1 7%
Agricultural and Biological Sciences 1 7%
Immunology and Microbiology 1 7%
Unspecified 1 7%
Other 1 7%
Unknown 5 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2015.
All research outputs
#3,459,140
of 5,227,971 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#396
of 640 outputs
Outputs of similar age
#119,718
of 183,007 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#39
of 73 outputs
Altmetric has tracked 5,227,971 research outputs across all sources so far. This one is in the 29th percentile – i.e., 29% of other outputs scored the same or lower than it.
So far Altmetric has tracked 640 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 183,007 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.